Last reviewed · How we verify

Pro Root MTA

Islamic Azad University, Sanandaj · FDA-approved active Small molecule Quality 5/100

Pro Root MTA, developed by Islamic Azad University, Sanandaj, is a marketed drug with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but its key strength lies in its patented composition, which provides a competitive barrier until 2028. The primary risk is the potential for increased competition once the key patent expires in 2028.

At a glance

Generic namePro Root MTA
Also known asMineral Trioxide Aggregate
SponsorIslamic Azad University, Sanandaj
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: